Embryonal tumors are the most common brain tumors in infants less than 36 months. Histologically characterized as undifferentiated small, round cell tumors with divergent patterns of differentiation, these include medulloblastoma, the most common form of embryonal tumor, as well as supratentorial primitive neuroectodermal tumor, medulloepithelioma, ependymoblastoma, medullomyoblastoma, melanotic medulloblastoma, and atypical teratoid/rhabdoid tumor. All are similarly aggressive and have a tendency to disseminate throughout the central nervous system. Because of efforts to avoid craniospinal irradiation in an attempt to lessen treatment-related neurotoxicity, management of these tumors in infants is unique. Outcomes remain similarly poor among all the tumor types and, therefore, identification of specific molecular targets that have prognostic and therapeutic implications is crucial. The molecular and clinical aspects of the 3 most common aggressive infantile embryonal tumors, medulloblastoma, supratentorial primitive neuroectodermal tumor, and atypical teratoid/rhabdoid tumor, are the focus of this review.
Louis DN, Ohgaki H., Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
2.
Pomeroy SL, Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415:436-442.
3.
Crawford JR, MacDonald TJ, Packer RJMedulloblastoma in childhood: new biological advances. Lancet Neurol. 2007;6: 1073-1085.
4.
Bunin GR, Kuijten RR, Buckley JD, Rorke LB, Meadows ATRelation between maternal diet and subsequent primitive neuroectodermal brain tumors in young children. N Engl J Med. 1993 ;329:536-541.
5.
McKean-Cowdin R., Preston-Martin S., Pogoda JM, Holly EA, Mueller BA, Davis RLParental occupation and childhood brain tumors: astroglial and primitive neuroectodermal tumors . J Occup Environ Med. 1998;40:332-340.
6.
Stavrou T., Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma . J Pediatr Hematol Oncol. 2001;23:431-436.
7.
Brown HG, Kepner JL, Perlman EJ, et al. ``Large cell/anaplastic'' medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol. 2000 ;59:857-865.
8.
Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94:552-560.
9.
Eberhart CG, Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol . 2004;63:441-449.
10.
Oliver TG, Read TA, Kessler JD, et al. Loss of patched and disruption of granule cell development in a pre-neoplastic stage of medulloblastoma. Development. 2005;132:2425-2439.
11.
Segal RA, Goumnerova LC, Kwon YK, Stiles CD, Pomeroy SLExpression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994;91:12867-12871.
12.
Grotzer MA, Janss AJ, Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol. 2000;18:1027-1035.
13.
Rubin JB, Rowitch DHMedulloblastoma: a problem of developmental biology. Cancer Cell. 2002;2:7-8.
14.
Zurawel RH, Allen C., Chiappa S., et al. Analysis of PTCH/SMO/ SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer. 2000;27:44-51.
15.
Hallahan AR , Pritchard JI, Hansen S., et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 2004;64:7794-7800.
16.
Taylor MD, Liu L., Raffel C., et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002;31:306-310.
17.
Raffel C., Jenkins RB, Frederick L., et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997;57:842-845.
18.
Dong J., Gailani MR, Pomeroy SL, Reardon D., Bale AEIdentification of PATCHED mutations in medulloblastomas by direct sequencing . Hum Mutat. 2000;16:89-90.
19.
Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade . Science. 2002;297:1559-1561.
20.
Romer JT, Kimura H., Magdaleno S., et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell. 2004;6: 229-240.
21.
Kimura H., Stephen D., Joyner A., Curran T.Gli1 is important for medulloblastoma formation in Ptc1+/- mice. Oncogene. 2005;24:4026-4036.
22.
Herms J., Neidt I., Lüscher B., et al. C-MYC expression in medulloblastoma and its prognostic value . Int J Cancer. 2000;89: 395-402.
23.
Gajjar A., Hernan R., Kocak M., et al. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004;22:984-993.
24.
Di C., Liao S., Adamson DC, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res. 2005;65:919-924.
25.
De Haas T., Oussoren E., Grajkowska W., et al. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol. 2006;65:176-186.
26.
Thompson MC , Fuller C., Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924-1931.
27.
MacDonald TJ , Brown KM, LaFleur B., et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease . Nat Genet. 2001;29: 143-152.
28.
Pan E., Pellarin M., Holmes E., et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005;11:4733-4740.
Erdem E., Zimmerman RA, Haselgrove JC, Bilaniuk LT, Hunter JVDiffusion-weighted imaging and fluid attenuated inversion recovery imaging in the evaluation of primitive neuroectodermal tumors. Neuroradiology . 2001;43:927-933.
31.
Vezina LG, Packer RJInfratentorial brain tumors of childhood. Neuroimaging Clin N Am. 1994;4:423-436.
32.
Zimmerman RA , Bilaniuk LT, Pahlajani H.Spectrum of medulloblastomas demonstrated by computed tomography. Radiology. 1978;126:137-141.
33.
Zimmerman RA , Bilaniuk LT, Rebsamen S.Magnetic resonance imaging of pediatric posterior fossa tumors. Pediatr Neurosurg. 1992;18:58-64.
34.
Evans AE, Jenkin RD, Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone . J Neurosurg.1990;72:572-582.
35.
Gajjar A., Fouladi M., Walter AW, et al. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol. 1999;17:1825-1828.
36.
Rood BR, Macdonald TJ, Packer RJCurrent treatment of medulloblastoma: recent advances and future challenges . Semin Oncol. 2004;31:666-675.
37.
Gilbertson RJ, Pearson AD, Perry RH, Jaros E., Kelly PJPrognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer. 1995;71:473-477.
38.
Min HS, Lee YJ, Park K., Cho BK, Park SHMedulloblastoma: histopathologic and molecular markers of anaplasia and biologic behavior. Acta Neuropathol. 2006;112:13-20.
39.
Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DWCombined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res. 2004;10:5482-5493.
40.
Ray A., Ho M., Ma J., et al. A clinicobiological model predicting survival in medulloblastoma . Clin Cancer Res. 2004;10: 7613-7620.
41.
Rutkowski S. , Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978-986.
42.
Albright AL , Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P.Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery . 1996;38:265-271.
43.
Polkinghorn WR, Tarbell NJMedulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 2007;4:295-304.
44.
Thomas PR, Deutsch M., Kepner JL, et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol. 2000;18: 3004-3011.
45.
Taylor RE, Bailey CC, Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21:1581-1591.
46.
Bailey CC, Gnekow A., Wellek S., et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Med Pediatr Oncol.1995;25:166-178.
47.
Walter AW, Mulhern RK, Gajjar A., et al. Survival and neurodevelopmental outcome of young children with medulloblastoma at St Jude Children's Research Hospital. J Clin Oncol. 1999;17: 3720-3728.
48.
Ris MD, Packer R., Goldwein J., Jones-Wallace D., Boyett JMIntellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol. 2001;19:3470-3476.
49.
Radcliffe J. , Packer RJ, Atkins TE, et al. Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy . Ann Neurol. 1992;32: 551-554.
50.
Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol. 2001;19:480-487.
51.
Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328:1725-1731.
52.
Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol. 1994;12:1607-1615.
53.
Dupuis-Girod S., Hartmann O., Benhamou E., et al. Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma?J Neurooncol . 1996;27:87-98.
54.
Geyer JR, Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol. 2005;23:7621-7631.
55.
Thorarinsdottir HK, Rood B., Kamani N., et al. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer. 2007;48:278-284.
56.
Sung KW, Yoo KH, Cho EJ, et al. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2007;48: 408-415.
57.
Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6:573-580.
58.
Kellie SJ, Wong CK, Pozza LD, et al. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children. Med Pediatr Oncol. 2002;39:168-174.
59.
Blaney SM, Boyett J., Friedman H., et al. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001. J Clin Oncol. 2005;23:525-531.
60.
Fruhwald MC , O'Dorisio MS, Dai Z., et al. Aberrant hyper-methylation of the major breakpoint cluster region in 17p11.2 in medulloblastomas but not supratentorial PNETs. Genes Chromosomes Cancer.2001;30:38-47.
61.
Inda MM, Mercapide J., Munoz J., et al. PTEN and DMBT1 homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol Rep. 2004;12:1341-1347.
62.
Reddy AT, Janss AJ, Phillips PC, Weiss HL, Packer RJOutcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer . 2000;88:2189-2193.
63.
MacDonald TJ , Rood BR, Santi MR, et al. Advances in the diagnosis, molecular genetics, and treatment of pediatric embryonal CNS tumors. Oncologist. 2003;8:174-186.
64.
Cohen BH, Zeltzer PM, Boyett JM, et al. Prognostic factors and treatment results for supratentorial primitive neuroectodermal tumors in children using radiation and chemotherapy: a Childrens Cancer Group randomized trial. J Clin Oncol. 1995;13: 1687-1696.
65.
Marec-Berard P., Jouvet A., Thiesse P., Kalifa C., Doz F., Frappaz D.Supratentorial embryonal tumors in children under 5 years of age: an SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol. 2002;38:83-90.
66.
Fangusaro J. , Finlay . Radiation therapy approaches do not currently improve overall survival in young children with sPNET as compared to the Head Start I and II experience. Pediatr Blood Cancer . 2008;50:312-318.
67.
Packer RJ, Biegel JL, Blaney S., et al. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002;24:337-342.
68.
Judkins AR, Burger PC, Hamilton RL, et al. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol . 2005;64: 391-397.
69.
Tekautz TM, Fuller CE, Blaney S., et al. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dosealkylator-based chemotherapy. J Clin Oncol. 2005;23:1491-1499.
70.
Gidwani P., Levy A., Goodrich J., Weidenheim K., Kolb EASuccessful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system. J Neurooncol. 2008;88:211-215.
